Bharat Book

Cancer Vaccine Partnering Terms and Agreements

Press Release   •   Dec 10, 2013 12:04 IST


Dec 10, 2013 : Bharat Book Bureau presents the new report, on 'Cancer Vaccine Partnering Terms and Agreements' provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 200 links to online copies of actual cancer vaccine deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of cancer vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer vaccine dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.It also provides the number of deals entered by top 50 big pharma, big biotech and most active dealmakers in cabcer vaccine partnering.

Chapter 3 provides a review of the leading cancer vaccine deals since 2007. Deals are listed by headline value, signed by big pharma and big biotech. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive and detailed review of cancer vaccine partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer vaccine partnering and dealmaking since 2007. This report comes with an additional appendix containing entire list of cancer vaccine dealmakers by Company A-Z, deal type and stage of development.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer vaccine technologies and products.

Report scope

Cancer Vaccine Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer vaccine trends and structure of deals entered into by leading companies worldwide.

Cancer Vaccine Partnering Agreements includes:

Trends in cancer vaccine dealmaking in the biopharma industry since 2007
Analysis of cancer vaccine deal structure
Access to headline, upfront, milestone and royalty data
Access to over 200 cancer vaccine deal records
The leading cancer vaccine deals by value since 2007
Includes adjuvant and drug delivery deals and alliances since 2007

In Cancer Vaccine Partnering Agreements, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific oncology therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Table of contents :

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in cancer vaccine dealmaking
2.1. Introduction
2.2. Cancer vaccine partnering over the years
2.3. Big pharma cancer vaccine dealmaking activity
2.3. Big biotech cancer vaccine dealmaking activity
2.4. Most active in cancer vaccine partnering
ImmunoCellular Therapeutics
National Cancer Institute
2.5. Cancer vaccine partnering by deal type
2.6. Cancer vaccine partnering by stage of development
2.7. Cancer vaccine partnering by cancer indication
2.8. Disclosed deal terms for cancer vaccine partnering
2.8.1 Cancer vaccine partnering headline values
2.8.2 Cancer vaccine deal upfront payments
2.8.3 Cancer vaccine deal milestone payments
2.8.4 Cancer vaccine royalty rates
2.9. The anatomy of cancer vaccine partnering
2.9. The anatomy of a cancer vaccine deal
2.9.a. Case study 1: Stemline Therapeutics, University of Pittsburgh- March 30 2012
2.9.b. Case study 2: University of Pennsylvania- VGX Pharmaceuticals: April 24, 2007

Chapter 3 – Leading cancer vaccine deals
3.1. Introduction
3.2. Top cancer vaccine deals by value

For more information kindly visit :

Related link :

About Bharat Book Bureau:

Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Follow us on twitter: 
Follow us on linked in : 
Our Blog : 

Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.